A major landmark in the field of immunotherapy for cancer occurred in 2016, when the phase III twin trials Checkmate 017 and Checkmate 057 investigated the use of the fully humanized IgG4 anti-PD-1 monoclonal antibody in patients with progressive non-small cell lung cancer [46,47]. Here, PDCD1 is linked to cancer.